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In the present paper, the synthesis, characterization, antimicrobial activity and in silico molecular docking study of  
6-((arylidene)amino)-4-(4-chlorophenyl)-2-oxo-1-((1-(2-oxo-2H-chromen-3-yl)ethylidene)amino)-1,2-dihydropyridine- 
3,5-dicarbonitriles 4a-o have been reported. Compounds 4d, 4g, 4j, 4k, 4m and 4o show significant activity. Structure 
determination of the synthesized compounds has been done by the standard spectroscopic techniques. It is observed that 
biological activity is influenced by electronic environment of the molecules. Electron withdrawing group at para position 
plays a major role for enhancing the biological activity for antibacterial activity and the electron donating group at para 
position for antifungal activity. Compounds 4a-o have been further evaluated for cytotoxicity on HeLa cells. From the 
cytotoxicity results, compounds have been found to possess low cytotoxicity with potent antimicrobial activity. 
Keywords: Medicinal chemistry, antibacterial, antifungal, cytotoxicity, molecular docking 
The synthesis and biological activities of coumarin 
based 2-pyridone derivatives 4a-o occupied an 
important position in heterocyclic chemistry as well 
as in medicinal chemistry. Coumarin derivatives 
displayed a wide range of medicinal activity1-6. 
Moreover, these derivatives were also found to 
possess very good antimicrobial activity as shown in 
the literature7-11. They are responsible for positive 
activity of several types of cancer including malignant 
melanoma, renal cell carcinoma, leukemia, prostate 
and breast cancer cells progression with less 
cytotoxicity12-15. Many currently available 
antimicrobial agents possessed coumarin skeleton 
such as Chlorobiocin and Novobiocin16 in their 
molecular frame work. 2-Pyridones denote versatile 
class of pharmacophores having very good 
therapeutic effect17 on several diseases. Heterocyclic 
compounds having 2-pyridone moiety showed various 
biological activities, such as analgesic18, anti-HIV19 
and antitumoral20. The most prominent examples of 
prescribed agents featuring the 2-pyridone  
nucleus include the Phosphodiester (PDE) III 
inhibitor Amrinone, Antifungal Ciclopirox, 
Cardiotonic agent Olprinone, Antitumor antibiotic 
Diazaquinomycin A, HIV-1 Inhibitors Pyridinone L 
as in shown Figure 1. 
In this paper, we have adopted the concept of 
Michael addition having α-β unsaturated carbonyl 
attack followed by hydrolytic cyclization with 
subsequent oxidative aromatization is the most 
common method used to synthesize 2-pyridone 
heterocycles21-23. In continuation of our previous work 
for searching novel pharmacophores with potent 
antimicrobial activity24-30, we have designed novel 
compounds having coumarin and 2-pyridone in a 
single molecular framework. Newly synthesized 
compounds were tested for antimicrobial potency and 
also evaluated cytotoxicity on HeLa cell line. Structural 
elucidation of newly synthesized compounds 4a-o was 
carried out by different analytical techniques like IR, 
NMR and mass spectrometry. 
 
Results and Discussion 
 
Chemistry 
The synthetic pathway of the titled compounds is 
given in Scheme I. 3-acetyl-2H-chromen-2-one (1) was 
synthesized with salicylaldehyde (A) and ethyl 
acetoacetate (B). Equimolar amount of the reaction 
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mixture was stirred at RT in the presence of piperidine 
as a catalyst. Compound (2) was prepared by the 
reaction of 3-acetyl-2H-chromen-2-one (1) and 2-
cyanoacetohydrazide which was mixed in an equimolar 
amount in methanol (30 mL), glacial acetic acid and 
refluxed at 50-60°C. In the consequent step, 
intermediate (2) (0.01 mol) was heated with 2-(4-
chlorobenzylidene)malononitrile (E) (0.01 mol).  
In this reaction, piperidine was used as a catalyst  
in ethanol (99%, 30 mL). As a result of this,  
reaction mixture furnished compound (3). Compound 
(3) (0.01 mol) was taken in ethanol and further 
 reacted with aromatic aldehydes to produced novel 
compounds (4a-o).  
Mechanism of the products 4a-o is proposed in the 
Scheme II. In the first step, hydrazone (A) undertook 
Michael addition with (B) and produced the 
intermediate (C). Intramolecular nucleophilic 
occurrence on the cyanide carbon was monitored  
to yield intermediate (D). Compound (E)  
was produced by the intramolecular electron  
transfer to nitrogen atom. In the final step, intermediate 
(E) was altered to targeted molecules by intermolecular 
nucleophilic attack on carbonyl carbon of various 
aromatic aldehydes (Scheme II). 
 
Discussion of Antimicrobial Activity 
 
Antibacterial studies 
All the synthesized compounds 4a-o were screened 
for their in vitro activity against several panels of 
bacteria by the conventional broth micro-dilution 
method using Chloramphenicol as a standard drug and 
the results are presented in the Table I. It was 
observed that compounds 4g (-4-NO2), 4j (-4-Cl), 4k 
(-4-F) and 4o (-4-Br) were the most effective 
antibacterial agents. Compounds 4g (-4-NO2) and 4o 
(-4-Br) exhibited excellent activity against P. 
aeruginosa and S. aureus with 2 to 4 fold higher MIC 
(12.5-25 mg/mL) than chloramphenicol. Compounds 
4j (-4-Cl) and 4k (-4-F) were the most effective 
against S. Pyogenes while compound 4j (-4-Cl) 
showed excellent activity against E. coli. Compounds 
4g (-4-NO2) and 4o (-4-Br) have a very good activity 
against S. Pyogenes while compounds 4j (-4-Cl) and 
4k (-4-F) were confirmed as very good agents against 
S. aureus. On the other hand, the presence of similar 
functional groups at the ortho position decrease the 
antibacterial activity as compared to 4e (-4-NO2) and 
4h (-4-Cl). Remarkable antibacterial activity is 
depicted by groups like -NO2, -F, -Cl and -Br. 
 
Antifungal studies 
Preliminary screening results showed that 
compounds 4d (-4-OH) and 4m (-4-OCH3) exhibited 
excellent activity against A. clavatus. While 
compound 4d (-4-OH) showed excellent activity 
against A. niger having 2 to 4 fold higher MIC (12.5-
25 mg/mL) in comparison with a standard drug 
Nystatin. The enhancement of the activity of 
compounds 4d and 4m (-4-OCH3) may be attributed 
 
 
Figure 1 — Commercially available drugs containing 2-pyridone nucleus 
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to the presence of electron releasing group at para 
position. When we installed hydroxy group at meta 
position in 4c (-3-OH), it possessed very good activity 
against A. niger and good activity against A. clavatus. 
Introduction of methoxy group in 4m (-4-OCH3) 
demonstrated very good potency against A. niger. 
 
Cytotoxicity studies 
In vitro cytotoxicity of 4a-o was tested against 
human cervical cancer cell line (HeLa) by the MTT 
colorimetric assay31,32 and Table II displayed  
IC50 values.  
Cytotoxicity results exposed that the derivatives 
4d, 4g, 4j, 4k, 4m and 4o having no toxicity at 
concentration level 100 µM (IC50 > 100 µM), while 
other compounds possessed moderate activity. It was 
confirmed that none of these tested compounds 
demonstrated any significant cytotoxic properties on 
HeLa cell lines. Above results indicated that none of 
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Scheme I — Synthetic route for the preparation of title compounds 4a-o 
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the compounds displayed cytotoxicity against 3T3 
cell lines (IC50 > 100 μM). 
 
Molecular docking 
Compounds 4b and 4e were used for docking poses 
representatives (Table III) as active molecules in 
transferase (1HNJ) of organism E. coli (strain K12). 
The beta-Ketoacyl-acyl carrier protein synthase III 
(FabH) is a condensing enzyme that plays central 
roles in fatty acid biosynthesis. This protein was 
downloaded from protein data bank (PDB). Binding 
of the ligands is shown in Figure 2, where, carbonyl  
 
 
Scheme II — Plausible mechanistic pathway for the synthesis of compounds 4a-o 
 
Table I — Antimicrobial screening results of compounds 4a-o 
Compd -R 
Minimum inhibitory concentration 
(MIC) for bacteria (µg/mL) 
Minimum inhibitory concentration 
(MIC) for fungi (µg/mL) 
E.c. P.a. S.a. S.p.  C.a. A.n. A.c. 
4a -H 250 250 150 150 200 500 500 
4b -2-OH 500 500 500 500 250 250 200 
4c -3-OH 500 500 250 500 500 50 100 
4d -4-OH 200 200 250 250 250 12.5 25 
4e -2-NO2 500 250 500 250 500 >1000 >1000 
4f -3-NO2 250 100 250 100 1000 1000 1000 
4g -4-NO2 100 25 12.5 50 1000 500 500 
4h -2-Cl 500 500 200 250 500 1000 1000 
4i -3-Cl 200 250 250 200 250 250 250 
4j -4-Cl 12.5 100 50 25 500 500 1000 
4k -4-F 100 100 50 12.5 250 >1000 >1000 
4l -3-OCH3 250 250 250 250 250 250 250 
4m -4-OCH3 250 200 500 500 100 50 25 
4n -3,4,5-(OCH3)3 500 500 250 500 200 500 500 
4o -4-Br 100 25 25 50 1000 >1000 >1000 
Chloramphenicol 50 50 50 50 − − − 
Nystatin − − − − 100 100 100 
Escherichia coli (E.c.) MTCC-442; Pseudomonas aeruginosa (P.a.) MTCC-441; Staphylococcus aureus (S.a.) MTCC-96; Streptococcus 
pyogenes (S.p.) MTCC-443; Candida albicans (C.a.) MTCC-227; Aspergillus niger (A.n.) MTCC-282; Aspergillus clavatus (A.c.) 
MTCC-1323. 
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>C=O has hydrogen bonding with TYR 639 and ARG 
630, and TYR 639 have pi-pi interaction with 
coumarin ring. 
 
Experimental Section 
 
Preparation of 3-acetyl-2H-chromen-2-one, 1 33 
and (E)2-(4-chlorobenzylidene)malononitrile 34 as 
per the literature method 
 
Preparation of 2-cyano-N'-(2-(2-oxo-2H-chromen-
3-yl)propylidene)acetohydrazide, 2 
A mixture of 3-acetyl-2H-chromen-2-one 1 
(0.01mol) and 2-cyanoacetohydrazide (0.01 mol) in 
methanol (30 mL) was refluxed for 14 h and then 
cooled down to RT. The separated crystals were 
filtered, air dried and recrystallized from ethanol 
(95%). Yield: 72%, m.p. 159°C. Anal. Calcd for 
C15H13N3O3: C, 63.60; H, 4.63; N, 14.83. Found: C, 
63.63; H, 4.56; N, 14.76%. 
 
Preparation of 6-amino-4-(4-chlorophenyl)-2-oxo-
1-((1-(2-oxo-2H-chromen-3-yl)ethylidene)amino)-1,2-
dihydropyridine-3,5-dicarbonitrile, 3 
A mixture containing 2-cyano-N'-(2-(2-oxo-2H-
chromen-yl)propylidene) acetohydrazide 2 (0.01 
mol), (E)-2-(4-chlorobenzylidene)malononitrile (0.01 
Table II — Levels of cytotoxicity prompted by selected 
compounds on HeLa cells 
Compd Cytotoxicity (IC50 µM) a 
HeLa b 
4c >100 
4d 97.56 
4g >100 
4j >100 
4k 98.16 
4m 96.88 
4o >100 
Doxorubicin 3.24 
a IC50 is the concentration required to inhibit 50% of cell growth 
b HeLa human cervical cancer cell line 
 
Table III — Docking score 
Compd Transferase 
(g Score) 
4b −0.946 
4e −0.831 
4d −0.551 
4g −0.475 
4c −0.073 
4l 0.509 
4f 1.391 
Chloroamphinicol −2.538 
Organism: E. coli 
 
 
 
Figure 2 — Molecular docking poses of 4b A (2D), B (3D). 4e A1 (2D), B1 (3D). 
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mol) and 2 drops of piperidine in ethanol (95%)  
(30 mL) was refluxed for 22 h. The mixture was then 
cooled down to RT and diluted with a few drops of 
water. The crystals formed were filtered, air dried and 
recrystallized from ethanol. Yield: 68%, m.p. 190°C. 
Anal. Calcd for C24H14ClN5O3: C, 63.24; H, 3.10; N, 
15.36. Found: C, 63.27; H, 3.04; N, 15.43%. 
 
General procedure of preparation of 6-
((benzylidene)amino)-4-(4-chlorophenyl)-2-oxo-1- 
((1-(2-oxo-2H-chromen-3-yl)ethylidene)amino)-1,2-
dihydropyridine-3,5-dicarbonitrile, 4a-o 
Compound 3 (0.01mol), benzaldehyde (0.01 mol) 
and ethanol (95%) (30 mL) were taken in a round 
bottom flask and refluxed for 12 h. Separated solid 
was filtered, dried and recrystallized from ethanol 
(95%). Yield: 73%. m.p. 157°C. Anal. Calcd for 
C31H18ClN5O3: C, 68.45; H, 3.34; N, 12.87. Found: C, 
68.39; H, 3.39; N, 12.81%. 
6-((Benzylidene)amino)-4-(4-chlorophenyl)-2-
oxo-1-((1-(2-oxo-2H-chromen-3-yl)ethyli dene) 
amino)-1,2-dihydropyridine-3,5-dicarbonitrile, 4a: 
Yield: 73%. m.p. 157-161°C. IR (KBr): 2927 (C-H, 
CH3), 2209 (-C≡N stretching, nitrile group), 1731 
(>C=O stretching, coumarin ring), 1564, 1597 
(>C=N-, >C=C< stretching, aromatic ring), 1588, 
1407 (C-H bending, -CH=N linkage), 1254 (C-O-C 
coumarin ring), 729 (C-Cl stretching) cm−1; 1H NMR 
(300 MHz, DMSO-d6): δ 9.18 (s, 1H, Ar-CH=N-), 
8.91 (s, 1H, C4 proton of coumarin), 7.25-7.89 (m, 
13H, Ar-H of coumarin ring and phenyl ring), 1.38 (s, 
3H, -C(CH3)=N-); 13C NMR (100 MHz, DMSO-d6): δ 
14.4, 114.5, 115.5, 115.9(2), 116.3, 118.2, 123.1, 
125.1, 127.7, 128.5, 128.8 (2), 128.9 (2), 129.4 (2), 
130.3 (2), 130.8, 131.2, 133.2 (2), 133.5, 153.1, 
153.4, 153.6, 155.4, 159.6, 160.0, 163.8, 169.6; 
LCMS: m/z 543.11 (M+). Anal. Calcd for 
C31H18ClN5O3: C, 68.45; H, 3.34; N, 12.87. Found: C, 
68.39; H, 3.39; N, 12.81%. 
 
Conclusion 
We have concluded on the basis of the biological 
activity results that the titled compounds 4a-o depend 
on the different types of substituent pattern on phenyl 
ring. Many of the synthesized motifs (4g, 4j, 4k and 
4o) having electron withdrawing atoms /groups such 
as halogen and nitro at para and meta positions 
showed potent antibacterial results while compounds 
4d and 4m having electron donating groups at para 
position showed potent antifungal results. The para 
position was more favorable as per the antimicrobial 
activity data of the compounds. Compounds (4d, 4g, 
4j, 4k, 4m and 4o) revealed notable cytotoxic action. 
This new class of novel coumarin linked 2-pyridone 
scaffolds can be optimized to get lead for further 
generation of antimicrobial agents. Therefore, the 
in silico studies and the biological activity can be 
specifically related with each other and optimization 
of potent molecules recognized in the present study 
can be taken out for further progress. 
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